TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07893288: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Three-Arm Study to Evaluate the Effects of 3-Week Supplementation With Single (THRIVE4U(TM) TG Lipase) and Combination Lipase (THRIVE4U(TM) Spectrum Lipases)

Sponsor: Danisco · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 50 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,030,400

Rescue Site Savings

+$5,954,420

Unlock Full NCT07893288 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07893288 Rescue Dossier →